A study found that nemolizumab doses of 30 mg and 60 mg, when used with topical corticosteroid treatment, were effective in reducing itch scores in adolescent patients with prurigo nodularis. The highest mean percentage reduction in itch scores was seen in the 30 mg group at 61.1%, followed by the 60 mg group at 56% and the placebo group at 18.6%. Patients treated with nemolizumab also showed improvements in sleep and quality of life outcomes. Adverse events were reported at similar rates across all groups, with the most common events being vaccination complication, eczema, erythema, dermatitis, and folliculitis.
Source link
Adding nemolizumab to topical corticosteroid treatment improves prurigo nodularis
